Related Experiment Video
Updated: Aug 19, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Use of an implantable drug delivery system for refractory chronic sickle cell pain
Thomas J Smith1, Patrick J Coyne, Wally R Smith
1VCU Sickle Cell Anemia Program and Thomas Palliative Care Unit of Virginia Commonwealth University Medical Center, Richmond, VA, USA. tsmith@hsc.vcu.edu
Abstract:
An increasing number of chronic sickle cell patients are being treated with sustained-release opioids in the same manner as cancer patients. In a randomized clinical trial of patients with refractory cancer pain, implantable intrathecal drug delivery systems (IDDS) improved clinical success compared to comprehensive medical management alone. We implanted IDDS pumps in two sickle cell patients with refractory bone pain. Both patients achieved rapid and sustained relief of pain, with dramatic reduction in the use of as-needed opioids, crises, and admissions. IDDS may offer relief for sickle cell patients with refractory pain. A prospective trial with more participants is planned.
Related Concept Videos
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Ophthalmic Drug Delivery Systems
Intrauterine Drug Delivery Systems
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Site-Targeted

